NCT03755791 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 432
- group Id
- BG001
- value
- 188
- group Id
- BG002
- value
- 217
- group Id
- BG003
- value
- 837
- units
- Participants
- groups
- description
- Participants received 40 mg cabozantinib oral tablets once daily + 1200 mg IV infusion of atezolizumab once every 3 weeks for up to 38 months.
- id
- BG000
- title
- Experimental Arm: Cabozantinib + Atezolizumab
- description
- Participants received 60 mg cabozantinib oral tablets once daily for up to 38 months.
- id
- BG001
- title
- Single-Agent Cabozantinib
- description
- Participants received 400 mg sorafenib oral tablets twice daily for up to 38 months.
- id
- BG002
- title
- Control Arm: Sorafenib
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 234
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 112
- group Id
- BG003
- value
- 443
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 198
- group Id
- BG001
- value
- 91
- group Id
- BG002
- value
- 105
- group Id
- BG003
- value
- 394
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 72
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 133
- title
- Female
- measurements
- group Id
- BG000
- value
- 360
- group Id
- BG001
- value
- 158
- group Id
- BG002
- value
- 186
- group Id
- BG003
- value
- 704
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 78
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 352
- group Id
- BG001
- value
- 158
- group Id
- BG002
- value
- 183
- group Id
- BG003
- value
- 693
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 66
- title
- Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 127
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 72
- group Id
- BG003
- value
- 263
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 14
- title
- Black/African American
- categories
- measurements
- group Id
- BG000
- value
- 217
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 111
- group Id
- BG003
- value
- 423
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 33
- group Id
- BG003
- value
- 137
- title
- Other than specified
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The Intent-to-Treat (ITT) population consisted of all participants who were randomized to any of the three study treatment arms, regardless of whether they received any study treatment.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 432
- group Id
- BG001
- value
- 188
- group Id
- BG002
- value
- 217
- group Id
- BG003
- value
- 837
- units
- Participants
- groups
- description
- Participants received 40 mg cabozantinib oral tablets once daily + 1200 mg IV infusion of atezolizumab once every 3 weeks for up to 38 months.
- id
- BG000
- title
- Experimental Arm: Cabozantinib + Atezolizumab
- description
- Participants received 60 mg cabozantinib oral tablets once daily for up to 38 months.
- id
- BG001
- title
- Single-Agent Cabozantinib
- description
- Participants received 400 mg sorafenib oral tablets twice daily for up to 38 months.
- id
- BG002
- title
- Control Arm: Sorafenib
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 234
- group Id
- BG001
- value
- 97
- group Id
- BG002
- value
- 112
- group Id
- BG003
- value
- 443
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 198
- group Id
- BG001
- value
- 91
- group Id
- BG002
- value
- 105
- group Id
- BG003
- value
- 394
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 72
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 133
- title
- Female
- measurements
- group Id
- BG000
- value
- 360
- group Id
- BG001
- value
- 158
- group Id
- BG002
- value
- 186
- group Id
- BG003
- value
- 704
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 21
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 78
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 352
- group Id
- BG001
- value
- 158
- group Id
- BG002
- value
- 183
- group Id
- BG003
- value
- 693
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 66
- title
- Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 127
- group Id
- BG001
- value
- 64
- group Id
- BG002
- value
- 72
- group Id
- BG003
- value
- 263
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 14
- title
- Black/African American
- categories
- measurements
- group Id
- BG000
- value
- 217
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 111
- group Id
- BG003
- value
- 423
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 33
- group Id
- BG003
- value
- 137
- title
- Other than specified
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The Intent-to-Treat (ITT) population consisted of all participants who were randomized to any of the three study treatment arms, regardless of whether they received any study treatment.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle